Loading...

PE anti-human CD274 (B7-H1, PD-L1) Antibody

Pricing & Availability
Clone
29E.2A3 (See other available formats)
Regulatory Status
RUO
Other Names
Programmed cell death ligand 1 (PD-L1), B7 homolog 1 (B7-H1)
Isotype
Mouse IgG2b, κ
Ave. Rating
Submit a Review
Product Citations
publications
29E.2A3_PE_CD274_Antibody_FC_091013
PHA-stimulated (3 days) human peripheral blood lymphocytes were stained with CD274 (clone 29E.2A3) PE (filled histogram) or mouse IgG2b, κ PE isotype control (open histogram).
  • 29E.2A3_PE_CD274_Antibody_FC_091013
    PHA-stimulated (3 days) human peripheral blood lymphocytes were stained with CD274 (clone 29E.2A3) PE (filled histogram) or mouse IgG2b, κ PE isotype control (open histogram).
See PE spectral data
Cat # Size Price Quantity Check Availability Save
329705 25 tests 95€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
329706 100 tests 211€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD274, also known as PD-L1 and B7-H1, is type I transmembrane glycoprotein that serves as a ligand for CD279 (PD-1). This interaction is believed to regulate the balance between the stimulatory and inhibitory signals needed for responses to microbes and maintenance of self-tolerance. CD274 is involved in the costimulation of T cell proliferation and IL-10 and IFN-γ production in an IL-2-dependent and CD279-independent manner. Conflicting data has shown that CD274 can inhibit T cell proliferation and cytokine production, and alternatively, enhance T cell activation. Other studies suggest that CD274 may signal bidirectionally, raising interesting implications for its expression in a wide variety of cell types, including T and B cells, antigen-presenting cells, and nonhematopoietic cells.

Product Details
Technical data sheet

Product Details

Reactivity
Human
Antibody Type
Monoclonal
Host Species
Mouse
Immunogen
Full length human PD-L1
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA)
Preparation
The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions.
Concentration
Lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood.

Excitation Laser
Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes

Clone 29E.2A3 is reported to recognize an epitope on PD-L1 within the PD-L1-CD80 binding region5. Additional reported applications (for the relevant formats) include: blocking1-3 and immunohistochemical staining of acetone-fixed frozen sections1. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 329715, 329716, 329745 - 329748). 

It has been observed that clone 29E.2A3 is able to bind to Alexa Fluor® 700 antibody conjugates during multi-color immunofluorescent staining. This interaction can be resolved by sequentially staining with the 29E.2A3 antibody first and then followed by the Alexa Fluor® 700 conjugate of interest.

Clone 29E.2A3 does not work in Western blot applications7.

Application References

(PubMed link indicates BioLegend citation)
  1. Brown J, et al. 2003. J. Immunol. 170:1257. (FC, IHC, Block)
  2. Radziewicz H, et al. 2007. J. Virol. 81:2545. (Block)
  3. Nakamoto N, et al. 2009. PLoS Pathog. 5:e1000313. (Block)
  4. Barsoum IB, et al. 2014. Cancer Res. 74:665. PubMed
  5. Haile, S et al. 2013. J. Immunol. 191:2829.
  6. RL M, et al. 2015. PNAS. 112:6506-6514. PubMed
  7. Mahoney KM, et al. 2015. Cancer Immunol. Res. 3:1308.
Product Citations
  1. Kagoya Y, et al. 2018. Nat Commun. 9:1915. PubMed
  2. Rolfes V, et al. 2018. Oncotarget. 9:27460. PubMed
  3. Wu L, et al. 2018. Oncol Lett. 15:9507. PubMed
  4. Lin JR et al. 2018. eLife. 7 pii: e31657. PubMed
  5. Zhao Y et al. 2018. Cell reports. 24(2):379-390 . PubMed
  6. Su S et al. 2018. Cell. 175(2):442-457 . PubMed
  7. Tran L, et al. 2017. Cancer Immunol Res. 5:1141. PubMed
  8. Tsukamoto M, et al. 2019. Cancer Sci. 110:310. PubMed
  9. Iwasa M, et al. 2019. Oncotarget. 10:1903. PubMed
  10. Bryson BD, et al. 2019. Nat Commun. 10:2329. PubMed
  11. Zong Z, et al. 2019. Front Immunol. 10:1643. PubMed
  12. Souriant S, et al. 2019. Cell Rep. 26:3586. PubMed
  13. Richardson JR, et al. 2018. Front Immunol. 2.182638889. PubMed
  14. Suzuki D, et al. 2020. Stem Cell Reports. 14:49. PubMed
  15. Kim DH, et al. 2019. Exp Mol Med. 51:94. PubMed
  16. Schott DS, et al. 2017. Oncotarget. 8:72755. PubMed
  17. Sucker A, et al. 2017. Nat Commun. 8:15440. PubMed
  18. Jiang G, et al. 2020. Aging (Albany NY). 12:11466. PubMed
  19. Xu H, et al. 2010. J Immunol. 185:7340. PubMed
  20. Durand-Panteix S, et al. 2012. J Immunol. 189:181. PubMed
  21. Padet L, et al. 2014. Immunobiology. 219:687. PubMed
  22. Nduom E, et al. 2016. Neuro Oncology. 18: 195 - 205. PubMed
  23. Jutz S, et al. 2016. J Immunol Methods. 430:10-20. PubMed
  24. Rosskopf S, et al. 2016. Sci Rep. 6:31580. PubMed
  25. Dan J, et al. 2016. J Immunol. 197: 983 - 993. PubMed
  26. Guan H, et al. 2016. Sci Rep. 6:35651. PubMed
  27. Lundell A, et al. 2017. Sci Rep. 7:39904. PubMed
  28. Ye Y, et al. 2020. Genome Med. 0.557638889. PubMed
  29. Sam J, et al. 2020. Front Oncol. 10:575737. PubMed
  30. Park JA, et al. 2020. J Hematol Oncol. 0.661111111. PubMed
  31. Rydyznski Moderbacher C, et al. 2020. Cell. 183(4):996-1012.e19. PubMed
  32. Zhang C, et al. 2020. Front Oncol. 0.944444444. PubMed
  33. Mao R, et al. 2020. Cancer Sci. 111:3174. PubMed
  34. Fan Z, et al. 2020. EMBO Mol Med. 12:e11571. PubMed
  35. Sugawara E, et al. 2020. Autophagy. 1.323611111. PubMed
  36. Ye LL, et al. 2020. Annals of Translational Medicine. 8(24):1647. PubMed
  37. Soday L, et al. 2021. Frontiers in Immunology. 12:600056. PubMed
  38. Mineo M, et al. 2020. Molecular Cell. 78(6):1207-1223.e8. PubMed
  39. Kwak T, et al. 2020. Cell Reports. 33(13):108571. PubMed
  40. Dai X, et al. 2021. Molecular Cell. 81(11):2317-2331.e6. PubMed
  41. Ng KW, et al. 2019. eLife. 0.333333333333333. PubMed
  42. Kenty JH, et al. 2021. STAR Protocols. 2(3):100675. PubMed
  43. Li H, et al. 2021. Adv Sci (Weinh). 2001596:8. PubMed
  44. Gilardini Montani MS, et al. 2020. Br J Cancer. 123:298. PubMed
  45. Okita R, et al. 2021. Thorac Cancer. 12:775. PubMed
  46. Wu Y, et al. 2021. Nat Commun. 12:2346. PubMed
  47. Zhang H, et al. 2021. Adv Sci (Weinh). 8:2003404. PubMed
  48. Wang Y, et al. 2021. Front Immunol. 12:654463. PubMed
  49. Geuijen C, et al. 2021. Nat Commun. 12:4445. PubMed
  50. Huang X, et al. 2021. Nat Nanotechnol. 16:214. PubMed
  51. Zhou C, et al. 2021. Mol Ther. 29:1512. PubMed
  52. Katsurahara K, et al. 2021. Cancer Sci. 112:1026. PubMed
  53. Lei Y, et al. 2021. Clin Transl Immunology. 10:e1231. PubMed
  54. Roberts A, et al. 2021. Sci Rep. 11:4030. PubMed
  55. Zhang R, et al. 2021. Front Oncol. 10:581733. PubMed
  56. Fujiwara Y, et al. 2021. Pancreas. 50:405. PubMed
  57. Yoshino H, et al. 2021. Curr Issues Mol Biol. 43:153. PubMed
  58. Shao L, et al. 2021. Cell Death Discov. 7:145. PubMed
  59. Curnock AP, et al. 2021. JCI Insight. 6:. PubMed
  60. Ahn A, et al. 2021. Cancers (Basel). 13:. PubMed
  61. Zhang H, et al. 2021. Cancer Gene Ther. Online ahead of print. PubMed
  62. Liang YH, et al. 2021. J Biomed Sci. 28:75. PubMed
  63. Darga EP, et al. 2021. PLoS One. 16:e0260124. PubMed
  64. Houtsma R, et al. 2021. STAR Protoc. 2:100864. PubMed
  65. Leonard NA, et al. 2021. Cancers (Basel). 13:. PubMed
  66. Yi K, et al. 2022. Front Immunol. 12:802795. PubMed
  67. Cui J, et al. 2022. Cancer Cell Int. 22:72. PubMed
  68. El Ahanidi H, et al. 2022. Front Oncol. 11:795242. PubMed
  69. Jarosch S, et al. 2022. STAR Protoc. 3:101374. PubMed
  70. Pathania AS, et al. 2022. Mol Ther Oncolytics. 25:308. PubMed
  71. Liu Y, et al. 2021. Oncogene. 40:2230. PubMed
  72. Tsuchiya K, et al. 2021. Oncoimmunology. 10:1962656. PubMed
  73. Shen C, et al. 2021. BMC Med. 19:283. PubMed
  74. Bouleau A, et al. 2022. J Nucl Med. 63:1259. PubMed
  75. Wang J, et al. 2022. Clin Transl Med. 12:e718. PubMed
  76. Oreskovic E, et al. 2022. Proc Natl Acad Sci U S A. 119:. PubMed
  77. Wang H, et al. 2022. J Cancer. 13:2126. PubMed
  78. Lee JM, et al. 2022. Lupus Sci Med. 9:. PubMed
  79. Hu H, et al. 2022. Exp Ther Med. 24:487. PubMed
  80. Rydyznski Moderbacher C, et al. 2022. J Clin Invest. :. PubMed
  81. Lau P, et al. 2022. Cell Mol Immunol. :. PubMed
  82. Hu Q, et al. 2021. Nat Biomed Eng. 5:1038. PubMed
  83. Zhou X, et al. 2022. J Nucl Med. 63:536. PubMed
  84. Jarosch S, et al. 2021. Cell Rep Methods. 1:100104. PubMed
  85. Guo Q, et al. 2022. Blood Adv. 6:5668. PubMed
  86. Herter JM, et al. 2022. Strahlenther Onkol. Online ahead of print. PubMed
  87. Zhang Z, et al. 2022. Clin Transl Med. 12:e1072. PubMed
  88. Li CY, et al. 2022. Int J Mol Sci. 23:. PubMed
  89. Kumagai Y, et al. 2020. J Surg Res. 246:52. PubMed
  90. Zhang Z, et al. 2022. Cancer Gene Ther. 29:722. PubMed
  91. Rodda LB, et al. 2022. Cell. 185:1588. PubMed
  92. Deepak HB, et al. 2022. Indian J Pharmacol. 54:183. PubMed
  93. He Y, et al. 2023. J Transl Med. 21:25. PubMed
  94. Hajibabaei S, et al. 2023. Sci Rep. 13:1003. PubMed
  95. Zhang W, et al. 2022. Dev Cell. 57:329. PubMed
  96. Chen L, et al. 2023. Immunology. 169:204. PubMed
  97. Fox DB, et al. 2023. NPJ Precis Oncol. 7:25. PubMed
  98. Wu Y, et al. 2023. Nat Cancer. 4:382. PubMed
  99. Li D, et al. 2023. Int J Oncol. 62:. PubMed
  100. Yi X, et al. 2023. Signal Transduct Target Ther. 8:107. PubMed
  101. Yang A, et al. 2023. J Immunother Cancer. 11:. PubMed
  102. Lafôrets F, et al. 2023. iScience. 26:106514. PubMed
  103. Hu X, et al. 2023. Nat Biotechnol. . PubMed
  104. Gu T, et al. 2023. Front Immunol. 14:1145028. PubMed
  105. Taylor J, et al. 2023. Front Immunol. 14:1119350. PubMed
RRID
AB_940366 (BioLegend Cat. No. 329705)
AB_940368 (BioLegend Cat. No. 329706)

Antigen Details

Distribution

T cells, B cells, NK cells, monocytes/macrophages, granulocytes and dendritic cells

Function
CD274 is involved in the costimulatory signal, essential for T lymphocyte proliferation and production of IL-10 and IFN-γ, in an IL-2-dependent and a PD-1-CD1-independent manner. Its interaction with PD-1-CD1 inhibits T-cell proliferation and cytokine production.
Ligand/Receptor
PD-1 (PDCD1)
Cell Type
B cells, Dendritic cells, Fibroblasts, Granulocytes, Macrophages, Monocytes, NK cells, T cells
Biology Area
Cancer Biomarkers, Costimulatory Molecules, Immunology
Molecular Family
Adhesion Molecules, CD Molecules, Immune Checkpoint Receptors
Antigen References

1. Sharpe A, et al. 2007. Nat. Immunol. 8:239.

Gene ID
29126 View all products for this Gene ID
UniProt
View information about CD274 on UniProt.org

Related FAQs

What type of PE do you use in your conjugates?
We use R-PE in our conjugates.
Go To Top Version: 7    Revision Date: 11.30.2016

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account